{
    "clinical_study": {
        "@rank": "18410", 
        "arm_group": [
            {
                "arm_group_label": "glimepiride", 
                "arm_group_type": "Experimental", 
                "description": "on the basis of metformin and glargine, the initial dose of glimepiride is 2 mg,qd (before breakfast), and adjust the dosage for fasting plasma glucose, dosage-adding indicator is the FPG\u22657.2, maximum dose of glimepiride is 4 mg/d per day."
            }, 
            {
                "arm_group_label": "Metformin and glargine", 
                "arm_group_type": "Active Comparator", 
                "description": "on the basis of Metformin and glargine,no glempiride addition. dose of glargine was adjust according to the FPG, with the  target less than 7.2mmol/l"
            }
        ], 
        "brief_summary": {
            "textblock": "All the guidelines suggest that metformin as the basis of type 2 diabetes medication, and\n      evidence is sufficient.At the same time the basal insulin injection once a day are more and\n      more widely used in diabetes patients in China.\n\n      This study aims to evaluate the efficacy and safety of adding glimepiride to type 2 diabetes\n      patients with inadequate glycemic control with combined therapy of metformin and basal\n      insulin."
        }, 
        "brief_title": "Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Understand the whole test process, voluntary and signed informed consent form\n\n          -  Men and women aged 35 to 70 years old\n\n          -  20\u2264BMI<35 Kg/m2\n\n          -  Diagnosed with type 2 diabetes\n\n          -  Undergoing metformin(Dose not less than 1000 mg/day)in combination with basal insulin\n             injection once a day\n\n          -  HbA1c7.0\uff0d11%\n\n          -  Patients should be able to self blood glucose monitoring\n\n        Exclusion Criteria:\n\n          -  sulfonylureas,glinides,TZDs use within 3 months before the study\n\n          -  Pregnant or lactating women\n\n          -  A history of ketoacidosis\n\n          -  Allergy to sulfonylureas or sulfa drug  patients\n\n          -  Apparent dysfunction of liver and kidney patients(ALT>2 times upper normal\n             limit,serum creatinine>1.2 times upper normal limit)\n\n          -  Poor blood pressure control(systolic pressure>180mmHg or diastolic blood\n             pressure>110mmHg)\n\n          -  heart disease,cardiac insufficiency,unstable angina pectoris,ECG indicates left\n             ventricle hypertrophy,severe anemia(Hb<9.0g/d1)\n\n          -  Severe diabetic nerve complications(ulcer of lower limb,neurogenic bladder)\n\n          -  BMI<20 orBMI\u226535kg/m2\n\n          -  Alcohol or drug abuse ,or can't collaborate due to mental disorder\n\n          -  Digestion and absorption function obstacle or Other endocrine disorders\n\n          -  Other chronic diseases required long-term glucocorticoid treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02026310", 
            "org_study_id": "yml2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "glimepiride", 
                "description": "on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.", 
                "intervention_name": "glimepiride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "glimepiride", 
                    "Metformin and glargine"
                ], 
                "intervention_name": "glargine and metformin", 
                "intervention_type": "Drug", 
                "other_name": "lantus"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Glargine", 
                "Insulin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "glimepiride", 
            "metformin", 
            "basal insulin", 
            "Hemoglobin A, Glycosylated", 
            "glucose fluctuation", 
            "hypoglycemia"
        ], 
        "lastchanged_date": "December 31, 2013", 
        "location": {
            "contact": {
                "email": "liqifu@yeah.net", 
                "last_name": "Qifu Li, PhD", 
                "phone": "+86 023 89011552"
            }, 
            "facility": {
                "address": {
                    "city": "Chongqing,", 
                    "country": "China", 
                    "state": "Chongqing", 
                    "zip": "400016"
                }, 
                "name": "The First Affiliated Hospital of Chongqing Medical University"
            }, 
            "investigator": {
                "last_name": "Yang Shumin, PhD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin", 
        "overall_contact": {
            "email": "liqifu@yeah.net", 
            "last_name": "Li Qifu, PhD", 
            "phone": "+86 023 89011510"
        }, 
        "overall_official": {
            "affiliation": "First Affiliated Hospital of Chongqing Medical University", 
            "last_name": "Li Qifu, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "24 weeks after treatment, HbA1c values' change compared with baseline", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks after treatment"
        }, 
        "reference": [
            {
                "PMID": "20335585", 
                "citation": "Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010 Mar 25;362(12):1090-101. doi: 10.1056/NEJMoa0908292."
            }, 
            {
                "PMID": "20445742", 
                "citation": "Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol. 2010;2010:476279. doi: 10.1155/2010/476279. Epub 2010 Apr 26. Review."
            }, 
            {
                "PMID": "18784090", 
                "citation": "Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. Epub 2008 Sep 10."
            }, 
            {
                "PMID": "10068412", 
                "citation": "Yki-J\u00e4rvinen H, Ryysy L, Nikkil\u00e4 K, Tulokas T, Vanamo R, Heikkil\u00e4 M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999 Mar 2;130(5):389-96. PubMed PMID: 10068412."
            }, 
            {
                "PMID": "12401758", 
                "citation": "Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, H\u00e4ring HU. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care. 2002 Nov;25(11):2065-73."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02026310"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chongqing Medical University", 
            "investigator_full_name": "Qifu Li", 
            "investigator_title": "Qifu Li, Chongqing Medical University", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "hypoglycemia events", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "source": "Chongqing Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Qifu Li", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}